Project Title

Eltrombopag and Early Refractory Immune Thrombocytopenia (ITP).

Official Title

A Multicentre, single arm, open label study evaluating the efficacy and safety of Eltrombopag (Revolade TM)) in patients with early refractory Immune Thrombocytopenia within 6 months of diagnosis.

Project Summary

This is an open label study, all patients will receive an oral tablet dose daily of eltrombopag based on their platelet count and ethnicity (patients from Japan have been shown to have an increased eltrombopag serum level by approximately 80% compared to Cuacasian patients). All patients will receive the study drug for 12 weeks and assessed for bleeding episodes and platelet count. Patients deemed to have responded will stay on eltrombopag with the opportunity to dose reduce to the lowest possible dose whilst maintaining a response over time. The study will run for 130 weeks (2 1/2 years) for those who continue to respond and the availability of the medication to patients beyond that.

Blood Disorder

  • Immune Thrombocytopenic Purpura

Patient Recruitment Details

Patient recruitment status: Closed

Number of Patients (globally)

39 participants.

Back to Archived Projects...